Business Description
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.13
Total Equity: $1.87B
Shares: 261,154,000
Total Debt: $1.21B
Cash: $415.10M
EBITDA: $212.90M
Total Debt: $1.21B
Cash: $415.10M
Revenue: $925.40M
Revenue: $925.40M
Revenue: $925.40M
Total Equity: $1.87B
Tax Rate: 8.9%
Equity: $1.87B
Total Debt: $1.21B
Cash: $415.10M
Current Liabilities: $316.10M
Long-Term Debt: $1.20B
Total Debt: $1.21B
Total Equity: $1.87B
Shares: 261,154,000
Shares: 261,154,000
CapEx: -$36.40M
Shares: 261,154,000
Stock Price: $18.45
Net Income: $28.80M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 6:46pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $668.3M | $717.8M | $800.9M | $860.8M | $925.4M |
| Cost of Revenue | $384.1M | $400.6M | $444.4M | $459.0M | $486.8M |
| Gross Profit | $284.2M | $317.2M | $356.5M | $401.8M | $438.6M |
| Operating Expenses | $352.9M | $615.0M | $378.4M | $377.0M | $387.1M |
| Operating Income | -$68.7M | -$297.8M | -$21.9M | $24.8M | $51.5M |
| Net Income | -$222.5M | -$276.9M | -$96.9M | -$36.1M | $28.8M |
| EBITDA | $92.6M | $104.3M | $149.0M | $179.0M | $212.9M |
| EPS | $-0.61 | $-1.53 | $-0.49 | $-0.18 | $0.13 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:46pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $84.0M | $73.5M | $128.8M | $175.2M | $415.1M |
| Total Current Assets | $453.4M | $480.6M | $538.6M | $594.7M | $897.8M |
| Total Assets | $3.1B | $2.7B | $2.7B | $2.6B | $3.6B |
| Current Liabilities | $221.0M | $244.3M | $265.7M | $263.5M | $316.1M |
| Long-Term Debt | $806.8M | $801.5M | $684.7M | $685.2M | $1.2B |
| Total Liabilities | $1.3B | $1.3B | $1.2B | $1.1B | $1.7B |
| Total Equity | $1.7B | $1.4B | $1.5B | $1.5B | $1.9B |
| Retained Earnings | -$131.6M | -$408.5M | -$505.4M | -$541.5M | -$512.7M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:46pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $900,000 | $39.4M | $95.2M | $99.1M | $143.3M |
| Capital Expenditure | -$17.6M | -$34.2M | -$37.1M | -$48.8M | -$36.4M |
| Free Cash Flow | -$16.7M | $5.2M | $58.1M | $50.3M | $106.9M |
| Acquisitions (net) | -$2.2B | -$6.6M | -$30.4M | -$1.0M | -$661.9M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$1.0M | -$2.0M | -$49.6M |
| Net Change in Cash | $84.2M | -$10.3M | $55.5M | $45.1M | $239.6M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 6:53am (2h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$928.4M $921.2M – $937.6M
|
$1.1B $1.1B – $1.2B
|
$1.2B $1.2B – $1.2B
|
$1.3B $1.3B – $1.3B
|
| EBITDA |
$313.4M $310.9M – $316.5M
|
$384.2M $380.9M – $388.6M
|
$413.8M $407.1M – $420.6M
|
$441.2M $436.1M – $446.2M
|
| Net Income |
$127.2M $124.6M – $129.8M
|
$139.3M $133.0M – $145.6M
|
$173.3M $155.2M – $191.4M
|
$211.5M $208.4M – $214.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:46pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +7.4% | +11.6% | +7.5% | +7.5% |
| Gross Profit Growth | +11.6% | +12.4% | +12.7% | +9.2% |
| Operating Income Growth | -333.5% | +92.6% | +213.2% | +107.7% |
| Net Income Growth | -24.4% | +65.0% | +62.7% | +179.8% |
| EBITDA Growth | +12.6% | +42.9% | +20.1% | +18.9% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:53am (2h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-13 | Kingsley Lawrence D | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-13 | Bockhorst Kenneth | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-13 | CASCELLA ROBERT | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-13 | Etzel Steven W. | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-13 | KUO JOHN W | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-13 | Markopoulos Jody | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-13 | Rege Sheila | A-Award | 7,383.00 | $0.00 | $0 |
| 2026-05-07 | Moore Christopher A. | S-Sale | 8,400.00 | $19.64 | $164,976 |
| 2026-05-06 | Logan Thomas D | G-Gift | 311,851.00 | $0.00 | $0 |
| 2026-04-01 | Ulrich Alison | F-InKind | 2,053.00 | $18.59 | $38,165 |
| 2026-04-01 | Schopfer Brian | F-InKind | 7,377.00 | $18.59 | $137,138 |
| 2026-04-01 | Moore Christopher A. | F-InKind | 1,903.00 | $18.59 | $35,377 |
| 2026-04-01 | Logan Thomas D | F-InKind | 22,614.00 | $18.59 | $420,394 |
| 2026-04-01 | Lee Emmanuelle | F-InKind | 4,680.00 | $18.59 | $87,001 |
| 2026-03-31 | Kingsley Lawrence D | A-Award | 1,104.00 | $17.32 | $19,121 |
| 2026-03-02 | Eloy Loic | A-Award | 15,577.00 | $0.00 | $0 |
| 2026-03-02 | Schopfer Brian | A-Award | 64,906.00 | $0.00 | $0 |
| 2026-03-02 | Schopfer Brian | F-InKind | 28,499.00 | $21.61 | $615,863 |
| 2026-03-01 | Schopfer Brian | F-InKind | 9,172.00 | $21.61 | $198,207 |
| 2026-03-01 | Ulrich Alison | A-Award | 5,552.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).